Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer

Cancer stem cells (CSCs) are often enriched after chemotherapy and contribute to tumor relapse. While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of diverse types of cancer, whether EGFR-TKIs are effective against chemoresistant CSCs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Yaping, Cang, Wei, Li, Quanfu, Liao, Xiaodong, Zhan, Mengna, Deng, Huayun, Li, Shengze, Jin, Wei, Pang, Zhi, Qiu, Xingdi, Zhao, Kewen, Chen, Guoqiang, Qiu, Lihua, Huang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879758/
https://www.ncbi.nlm.nih.gov/pubmed/31772161
http://dx.doi.org/10.1038/s41389-019-0179-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879758/
https://www.ncbi.nlm.nih.gov/pubmed/31772161
http://dx.doi.org/10.1038/s41389-019-0179-2

Ejemplares similares